HD-PLC-ALLIANCE
21.1.2020 02:02:05 CET | Business Wire | Press release
In Japan, the High-definition Power Line Communication (HD-PLC ) technology has been mostly used in PLC adapters and communication equipment so far. One major reason was the interpretation of the “Ministerial Order to Provide Technical Standards for Electrical Appliances and Materials” which applied to the integration of HD-PLC into home electric appliances and housing equipment. Recently, the efforts of the involved parties have been rewarded by the Notice issued on December 25, 2019 by the Ministry of Economy, Trade and Industry (METI) that partially revised the interpretation of the Ministerial Order. HD-PLC can now be integrated in home appliances and housing equipment.
The main advantages of HD-PLC over wireless technologies include an easy setup of communication networks, a high level of security, and low power consumption. Additionally, HD-PLC can be used on power lines, coaxial cables, telephone lines, and other existing lines which not only enables the deployment of networks in in-house environments such as homes, buildings, and factories, but also the deployment of large outdoor networks covering areas of some square kilometers.
Furthermore, HD-PLC is expected to play an important role in underground facilities and radio-shielded spaces in buildings and houses where wireless reception is bad, while users expects high-speed, low-latency applications be provided by next-generation 5G networks. HD-PLC can play a unique role by working in conjunction with 5G, Wi-Fi, Bluetooth, and other wireless technologies to enhance the quality of service of networks. The ministerial order revision has opened the way for consumers to buy stationary home appliances with build-in HD-PLC technology, making easy to build networks by simply connecting the equipment to an electric outlet. This will provide a new solution for interconnecting electric appliances.
Yoshiyuki Miyabe, Senior Managing Executive Officer of Panasonic Corporation, the founding company of the HD-PLC Alliance, sent us a message: “Panasonic’s fourth-generation HD-PLC technology has already been approved as the IEEE 1901a Standard. We are excited by the huge opportunities that the ministerial order revision has opened to make HD-PLC one of the most innovative core technologies in the age of IoT. Panasonic will take advantage of these opportunities to integrate the technology in many of our products and solutions, working toward its further development and expansion and offering new values to our customers.”
HD-PLC Alliance will continue to promote the use of HD-PLC in electric appliances and to provide certification of HD-PLC built-in machinery and equipment ensuring communication compatibility. Simultaneously, we will keep making efforts to improve the certification environment. With the motto “HD-PLC takes up the challenge of becoming the IoT solution that connects people’s living, industry, and the community,” we will keep contributing toward establishing universal standards and promoting wider use of HD-PLC compatible products.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200120005132/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom